ES009 / Elpiscience - LARVOL DELTA

A first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the LILRB2 inhibitor ES009 in patients with advanced solid tumors (SITC 2025) - P1 | "As a monotherapy, ES009 showed preliminary antitumor activity, supporting further clinical development.Trial Registration ClinicalTrials.gov ID: NCT06007482Ethics Approval This study obtained ethics approval from the Bellberry Human Research Ethics Committee, the number/ID of the approval was 2023-06-715. Participants gave informed consent before taking part."

Clinical • First-in-human • Metastases • P1 data • PK/PD data • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Submandibular Gland Cancer

A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Elpiscience Biopharma Australia Pty. Ltd. | Recruiting ➔ Completed | N=20 ➔ 12 | Trial completion date: Aug 2025 ➔ Feb 2025 | Trial primary completion date: Aug 2024 ➔ Feb 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Solid Tumor

Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of Anti-LILRB2 Antibody ES009 in Australia (Businesswire) - "Elpiscience Biopharmaceuticals...announced today that the first patient has been dosed in a Phase 1 clinical trial of its anti-LILRB2 monoclonal antibody ES009 in Australia. The objective of the trial is to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity."

Trial status • Oncology • Solid Tumor

A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Elpiscience Biopharma Australia Pty. Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Elpiscience Biopharma Australia Pty. Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor

ES009, a LILRB2-specific blocking antibody, reprograms myeloid cells into pro-inflammation phenotype and potentiates T cell activation (SITC 2022) - "Conclusions In summary, the anti-LILRB2 mAb ES009 has demonstrated great potential in the reversion of immune suppression in the TME, leading to promotion of anti-tumor immunity. We are currently advancing the development of ES009 into a clinical candidate."

IO biomarker • Oncology • Ovarian Cancer • Solid Tumor • ANGPT1

Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting (Businesswire) - "Elpiscience Biopharmaceuticals...presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting....Abstract No.: 1062 - LILRB2 is predominantly expressed in myeloid lineage cells. Human LILRB2 broadly binds to multiple ligands and contributes to immune suppression in the tumor microenvironment (TME). Anti-LILRB2 mAb ES009 has demonstrated superior effects in converting immunosuppressive myeloid cells into pro-inflammation phenotypes in in vitro and ex vivo models."

Preclinical • Oncology

Elpiscience Announces Five Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting (Businesswire) - "Elpiscience Biopharmaceuticals...announced it will have five poster presentations at the SITC 2022 Annual Meeting being held in Boston, Massachusetts from November 8-12. The posters will highlight studies on five innovative molecules including anti-SIRPα monoclonal antibody ES004, anti-LAG3 monoclonal antibody ES005, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, and PD-L1/SIRPα bispecific macrophage engager ES019."

Preclinical • Oncology